Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Novartis
Cantor Fitzgerald
Queensland Health
Chubb
Harvard Business School
US Army
QuintilesIMS
Mallinckrodt
Boehringer Ingelheim

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
Abstract:A synergistic pharmaceutical combination or composition is disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a histamine H.sub.2 receptor blocking agent, which increases intragastric pH, and an acid degradable antibacterial compound. In particular, the combination is directed to the treatment of infections by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds.
Inventor(s): Eek; Arne T. (Trosa, SE), Sjostrand; Sven E. (Sodertalje, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Filing Date:May 16, 1995
Application Number:08/442,382
Claims:1. A pharmaceutical composition for the treatment of gastritis and peptic ulcer, comprising a therapeutically effective amount of a histamine-H.sub.2 receptor blocking compound which increases intragastric pH and a therapeutically effective amount of an acid degradable antibacterial compound.

2. The composition according to claim 1 wherein the acid degradable antibacterial compound is a weak base antibiotic.

3. The composition according to claim 1 wherein the acid degradable antibacterial compound is a penicillin or a macrolide.

4. The composition according to claim 3 wherein the penicillin is benzylpenicillin and the macrolide is an erythromycin or a clarithromycin.

5. An oral pharmaceutical composition for the treatment of gastritis and peptic ulcer caused by Helicobacter pylori infections comprising as active ingredients,

(a) a therapeutically affective amount of a histamine-H.sub.2 blocker which is a compound with inhibiting effect on the gastric acid secretion which effect increases the intragastric pH; and

(b) a therapeutically affective amount of an acid degradable antibacterial compound.

6. The composition according to claim 5 wherein the acid degradable antibacterial compound is selected from the group consisting of a penicillin and a macrolide.

7. The composition according to claim 5 wherein the acid degradable antibacterial compound is a benzyl penicillin.

8. The composition according to claim 5 wherein the acid degradable antibacterial compound is selected from the group consisting of an erythromycin and a clarithromycin.

9. A synergistic pharmaceutical combination comprising from about 1 to 200 mg histamine-H.sub.2 blocker and from about 250 mg to 10 g of an acid degradable antibacterial compound for the treatment of gastritis and peptic ulcer.

10. A synergistic pharmaceutical combination of a therapeutically acceptable amount of a histamine H.sub.2 blocker and a therapeutically acceptable amount of an acid degradable antibacterial compound selected from the group consisting of an erythromycin, a clarithromycin and a penicillin for the oral treatment of gastritis and peptic ulcer.

11. A method for treatment of gastritis and peptic ulcer caused by Helicobacter pylori comprising orally first administering to a patient suffering therefrom a pharmaceutical composition comprising a therapeutically effective amount of a histamine-H.sub.2 blocker which is an inhibitor of the gastric acid secretion, and pharmaceutically acceptable carrier; and thereafter and concomitantly administering a therapeutically effective amount of at least one acid degradable antibacterial compound.

12. The method according to claim 11 wherein the acid degradable antibacterial compound is a penicillin or a macrolide.

13. The method according to claim 12, wherein the macrolide is selected from the group consisting of an erythromycin and clarithromycin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
US Department of Justice
Chinese Patent Office
Merck
Julphar
Farmers Insurance
Baxter
Healthtrust
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot